Platelet activation in patients with colorectal cancer

M. G. Sciulli, P. Filabozzi, S. Tacconelli, R. Padovano, E. Ricciotti, M. L. Capone, M. Grana, V. Carnevale, P. Patrignani

Research output: Contribution to journalArticlepeer-review


Aspirin may reduce the risk of colorectal neoplasia at doses similar to those recommended for the prevention of cardiovascular disease. Thus, we aimed to address whether enhanced platelet activation, as assessed by the measurement of the urinary excretion of 11-dehydro-TXB 2 (a major enzymatic metabolite of TXB 2), occurs in patients with colorectal cancer. In 10 patients with colorectal cancer, the urinary excretion of 11-dehydro-TXB 2 was significantly higher than in 10 controls, matched for sex, age and cardiovascular risk factors [1001(205-5571) versus 409(113-984) pg/mg creatinine, respectively, median (range), P2 levels, or in vivo, as assessed by urinary 11-dehydro-TXB 2 excretion. In conclusion, enhanced platelet activation occurs in colorectal cancer patients. Permanent inactivation of platelet COX-1 by low-dose aspirin might restore anti-tumor reactivity.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalProstaglandins, Leukotrienes and Essential Fatty Acids
Issue number2 SPEC. ISS.
Publication statusPublished - Feb 2005

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Platelet activation in patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this